Regeneron Pharmaceuticals’ profits from Dupixent underpriced, says Barclays

Investing.com Gold reports: Regeneron Pharmaceuticals’ profits from Dupixent underpriced, says Barclays. This is a premium/paywalled source, so the brief is based on headline and available metadata only.